[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586110":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":11,"studyPopulation":11,"armGroups":29,"interventions":42,"overallOfficials":52,"centralContacts":56,"locations":62,"responsibleParty":156,"collaborators":11,"id":158,"slug":11,"hasResults":159,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":11,"eligibilityCriteria":163,"healthyVolunteers":159,"sex":164,"minAge":165,"maxAge":11,"enrollmentInfo":166,"targetDuration":11,"studyType":169,"phases":170,"briefSummary":172,"conditions":173,"keywords":175,"overallStatus":65,"whyStopped":11,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},{"fullName":5,"class":6},"Neurocrine Biosciences","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56",null,"Baseline, Day 56",[14,16],{"measure":15,"description":11,"timeFrame":12},"Change from Baseline in Sheehan Disability Scale (SDS) Total Score at Day 56",{"measure":17,"description":11,"timeFrame":12},"Change from Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score at Day 56",{"allocation":19,"interventionModel":20,"interventionModelDescription":11,"primaryPurpose":21,"observationalModel":11,"timePerspective":11,"maskingInfo":22},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":23,"maskingDescription":11,"whoMasked":24},"QUADRUPLE",[25,26,27,28],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[30,36],{"label":31,"type":32,"description":33,"interventionNames":34},"NBI-1065845","EXPERIMENTAL","NBI-1065845 administered orally once a day.",[35],"Drug: NBI-1065845",{"label":37,"type":38,"description":39,"interventionNames":40},"Placebo","PLACEBO_COMPARATOR","Placebo identical in appearance to NBI-1065845 will be administered orally once a day.",[41],"Drug: Placebo",[43,49],{"type":44,"name":31,"description":45,"armGroupLabels":46,"otherNames":47},"DRUG","NBI-1065845 tablets",[31],[48],"TAK-653",{"type":44,"name":37,"description":50,"armGroupLabels":51,"otherNames":11},"Matching placebo tablets",[37],[53],{"name":54,"affiliation":5,"role":55},"Clinical Development Lead","STUDY_DIRECTOR",[57],{"name":58,"role":59,"phone":60,"phoneExt":11,"email":61},"Neurocrine Medical Information Call Center","CONTACT","1-877-641-3461","medinfo@neurocrine.com",[63,77,86,94,103,111,120,129,138,147],{"facility":64,"status":65,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":11},"Neurocrine Clinical Site","RECRUITING","Huntsville","Alabama","35801","United States","US",{"type":72,"coordinates":73},"Point",[74,75],-86.58594,34.7304,{"lat":75,"lon":74},{"facility":64,"status":65,"city":78,"state":79,"zip":80,"country":69,"countryCode":70,"cosmosGeoPoint":81,"geoPoint":85,"contacts":11},"Glendale","California","91206",{"type":72,"coordinates":82},[83,84],-118.25508,34.14251,{"lat":84,"lon":83},{"facility":64,"status":65,"city":87,"state":79,"zip":88,"country":69,"countryCode":70,"cosmosGeoPoint":89,"geoPoint":93,"contacts":11},"Irvine","92614",{"type":72,"coordinates":90},[91,92],-117.82311,33.66946,{"lat":92,"lon":91},{"facility":64,"status":65,"city":95,"state":96,"zip":97,"country":69,"countryCode":70,"cosmosGeoPoint":98,"geoPoint":102,"contacts":11},"Miami","Florida","33174",{"type":72,"coordinates":99},[100,101],-80.19366,25.77427,{"lat":101,"lon":100},{"facility":64,"status":65,"city":104,"state":96,"zip":105,"country":69,"countryCode":70,"cosmosGeoPoint":106,"geoPoint":110,"contacts":11},"Tampa","33607",{"type":72,"coordinates":107},[108,109],-82.45843,27.94752,{"lat":109,"lon":108},{"facility":64,"status":65,"city":112,"state":113,"zip":114,"country":69,"countryCode":70,"cosmosGeoPoint":115,"geoPoint":119,"contacts":11},"Atlanta","Georgia","30318",{"type":72,"coordinates":116},[117,118],-84.38798,33.749,{"lat":118,"lon":117},{"facility":64,"status":65,"city":121,"state":122,"zip":123,"country":69,"countryCode":70,"cosmosGeoPoint":124,"geoPoint":128,"contacts":11},"Boston","Massachusetts","02131",{"type":72,"coordinates":125},[126,127],-71.05977,42.35843,{"lat":127,"lon":126},{"facility":64,"status":65,"city":130,"state":131,"zip":132,"country":69,"countryCode":70,"cosmosGeoPoint":133,"geoPoint":137,"contacts":11},"Saint Charles","Missouri","63304",{"type":72,"coordinates":134},[135,136],-90.48123,38.78394,{"lat":136,"lon":135},{"facility":64,"status":65,"city":139,"state":140,"zip":141,"country":69,"countryCode":70,"cosmosGeoPoint":142,"geoPoint":146,"contacts":11},"The Bronx","New York","10461",{"type":72,"coordinates":143},[144,145],-73.86641,40.84985,{"lat":145,"lon":144},{"facility":64,"status":65,"city":148,"state":149,"zip":150,"country":69,"countryCode":70,"cosmosGeoPoint":151,"geoPoint":155,"contacts":11},"Mason","Ohio","45040",{"type":72,"coordinates":152},[153,154],-84.30994,39.36006,{"lat":154,"lon":153},{"type":157,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100586110",false,"NCT06911112","NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)","A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)","Key Inclusion Criteria:\n\n* Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder.\n* Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression.\n* Participant must have been taking oral antidepressants for at least 8 weeks and is willing to continue the same oral antidepressants at the same dose and frequency of administration throughout participation in the study.\n* Total Hamilton Depression Rating Scale-17 Item (HAM-D17) score ≥22 at screening and at study baseline (Day 1).\n* Willing and able to comply with all study procedures and restrictions in the opinion of the investigator.\n\nKey Exclusion Criteria:\n\n* A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than MDD.\n* Are considered by the investigator to be at imminent risk of suicide or injury to self or others.\n* Participants depressive symptoms have previously demonstrated nonresponse to electroconvulsive therapy (ECT) in the current major depressive episode.","ALL","18 Years",{"count":167,"type":168},200,"ESTIMATED","INTERVENTIONAL",[171],"PHASE3","The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.",[174],"Major Depressive Disorder",[176,177,174,31,48,178],"MDD","Depression","MADRS","2025-11-26",{"date":181,"type":182},"2025-12-01","ACTUAL",{"date":184,"type":182},"2025-03-31",{"date":186,"type":168},"2027-07",{"name":5,"class":6},10]